The QualityStocks Daily Thursday, April 26th, 2018

Today's Top 3 Investment Newsletters

Penny Picks (EYTH) +92.86%

AwesomeStocks (GNPX) +86.76%

QualityStocks (MIHI) +61.11%

The QualityStocks Daily Stock List

Northsight Capital, Inc. (NCAP)

AwesomePennyStocks, OTC Markets, Equity Clock, Marketwired, Investors Hub, MarketWatch, Barchart, The Street, Equities, Insider Monkey, Stockopedia, UptickNewswire, and WhaleWisdom reported on Northsight Capital, Inc. (NCAP), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Northsight Capital, Inc. consists of a portfolio of online Cannabis-related websites, which are undergoing development and operated by the Company. These sites incorporate numerous aspects of the Cannabis industry. The Company is now transitioning into two sectors. One is the Bitcoin ATM service industry. The other is its present cannabis advertising and media platform. Northsight Capital has its corporate headquarters in Scottsdale, Arizona. The Company’s shares trade on the OTC Markets Group’s OTCQB.

The Company does not sell or distribute any cannabis products. It is looking to acquire digital or publishing companies in the space.

Northsight Capital has its WeedDepot.com. It provides consumers with a geo-targeted map directory of medical and recreational dispensaries, head shops, doctors, attorneys and more within the Cannabis industry. Weed Depot has an entire platform of content suited for every aspect of advertising and marketing to consumers from all businesses in the cannabis industry.

In addition, the Company has its 420Careers.com. This is a top job site in the Cannabis space.  420Careers.com has 3,000 to 5,000 visitors daily and roughly 1 million page views monthly.

This past November, Northsight Capital announced that it signed a preliminary agreement to acquire 80 percent of Westcliff Technologies. At present, Westcliff operates a digital asset retail brokerage as “National Bitcoin ATM”. It also provides consumers the ability to purchase Bitcoin right away via a network of kiosks (ATM’s) located in the U.S.

The company has 24 kiosks producing an average of $180,000 per year each, or roughly $4 plus million a year. Moreover, it has transacted $9.2 million since inception in June of 2015. Westcliff Technologies has been working exclusively in the blockchain space since its beginning.

In addition, Northsight Capital is acquiring 49 percent of Westcliff Technologies’ ICO (Initial Coin Offering) and wallet platforms that are now under development and pre-Revenue.

Northsight Capital has completed its acquisition of Crush Mobile, LLC. Crush Mobile has about 900,000 members. It has developed a group of dating sites with a presence in the Latino, Israeli and African American communities.

Crush Mobile is now a part of Northsight Capital’s growing media group. Furthermore, Crush Mobile will be incorporating into its dating applications suite Northsight's "Joint Lovers" dating app that will center on the Cannabis space.

Northsight Capital, Inc. (NCAP), closed Thursday's trading session at $0.036, up 6.51%, on 70,314 volume with 13 trades. The average volume for the last 60 days is 86,919 and the stock's 52-week low/high is $0.0251/$0.14.

chart

Mobivity Holdings Corp. (MFON)

Investors Hub and Zacks reported previously on Mobivity Holdings Corp. (MFON), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Mobivity Holdings Corp. provides a platform for intelligent and personalized marketing in the real world. The Company leverages detailed purchase data and communications platforms to improve business results through understanding, predicting, and influencing consumer behavior. Mobivity helps restaurant and retail brands grow their business through increasing customer frequency, engagement, and spend. Mobivity Holdings has its corporate office in Arizona.

The Company drives better actions and informs decisions via connecting Point of Sale (POS) outcomes to the events and influences that caused them. Mobivity’s platform consists of software for phones, tablets PCs, and POS systems. These enable resellers, brands, and enterprises to market their products and services to consumers through text messages sent directly to consumers through mobile phones, mobile smartphone applications, as well as printed receipt content.

Mobivity has its SmartSuite Platform. With SmartSuite, restaurant and retail enterprises can unlock the power of customer, employee, and transaction data to continually adapt, optimize, and provide the most personalized, relevant, and targeted customer experiences.

SmartSuite is utilized to increase participation in one-to-one marketing and customer engagement through mobile first interactions. The Company’s SmartSMS and SmartReceipt products assist brands in aggressively interacting with a following of consumers who can help a client boost top-line sales by way of suggestive selling.

Along with the SmartSuite Platform, the Company’s products include SmartMessenger, SmartReceipt®, SmartScan, SmartAnalytics, SmartAds, Nutricate, Refer-a-Friend+, and Loyalty+.

In February, Mobivity Holdings announced the initial implementation and success metrics from its partnership with Round Table Pizza.  Global Franchise Group (GFG), the owners and operators of over 1,500 restaurant locations across five brands, including Round Table Pizza, recently launched Mobivity’s platform at Northern California Round Table Pizza locations.

The implementation of Mobivity solutions drove a greater than 40 percent increase in average customer spend. More than 1,000 participating Round Table Pizza guests per location chose to receive text-based communications.

Mobivity Holdings is pioneering a blockchain-powered platform for commerce and customer communication with brands. The Company has made announcements recently pertaining to the development of its platform to enable currency-based customer rewards programs and the precise tracking of offer and coupon redemptions.

This month, Mobivity Holdings announced that its partnership with Round Table Pizza and Global Franchise Group (GFG) has been expanded into a three-year relationship. It will now include the roll-out of Mobivity’s full re•currency platform to all Round Table Pizza locations across the country.

Mobivity Holdings Corp. (MFON), closed Thursday's trading session at $0.98, down 2.00%, on 104,338 volume with 11 trades. The average volume for the last 60 days is 15,757 and the stock's 52-week low/high is $0.55/$1.80.

chart

Gold Fields Limited (GFIOF)

The Street, StreetWise Reports, MiningFeeds, Stockhouse, 24hGold, StreetInsider, InvestorsHub, and StockChase reported on Gold Fields Limited (GFIOF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

An internationally diversified producer of gold, Gold Fields Limited’s vision is to be the worldwide leader in sustainable gold mining. The Company produces gold and holds gold reserves and resources in South Africa, Ghana, Australia, and Peru. It has seven operating mines in these nations with attributable annual gold-equivalent production of roughly 2.2 million ounces. Listed on the OTC Markets, Gold Fields has its head office in Sandton, Johannesburg, South Africa.

The Company has operated in South Africa since 1887, when Mr. Cecil John Rhodes and Mr. Charles Rudd created Gold Fields of South Africa. In 1932, Gold Fields of South Africa started mining the mineral-rich West Rand, where it discovered high-yielding gold deposits. A merger between Gold Fields of South Africa and Gencor in 1998 led to the establishment of Gold Fields Limited.

The Company has attributable gold Mineral Reserves of approximately 49 million ounces. It has gold Mineral Resources of approximately 104 million ounces. Attributable copper Mineral Reserves total 764 million pounds and Mineral Resources 4,881 million pounds.

Regarding its operations, Gold Fields has its Cerro Corona mine in Peru (Copper, Gold, Porphyry). In the West Africa region Gold Fields has its Tarkwa and Damang mines in Ghana (open pit gold mines).

In the South Africa region, the Company has its South Deep mine, which is an underground gold mine. In the Australia region, Gold Fields’ assets consist of a 100 percent interest in the St Ives, Agnew, and Granny Smith mines in the Yilgarn area of Western Australia. They also include a 50 percent interest in the Gruyere project with Gold Road.

For Q1 2018, Gold Fields’ attributable equivalent gold production for the quarter was 1 percent lower YoY (Year over Year) (10 percent lower Quarter over Quarter {QoQ}) at 490koz. Q1 2017 production included 14koz from Darlot, which was divested in Q4 2017.

All-in sustaining costs (AISC) were 6 percent lower YoY (flat QoQ) at US$955/oz. Moreover, all-in costs (AIC) were 3 percent higher YoY (3 percent higher QoQ) at US$1,150/oz.

Mr. Nick Holland, Gold Fields’ Chief Executive Officer, stated, “2018 is the second year of Gold Fields' reinvestment programme. Following a strong year in 2017, in Q1 2018 the Damang reinvestment project continued to progress according to plan, the Gruyere project has been impacted by severe weather and South Deep performed below expectation. However, the international operations continue to perform well, in most cases exceeding their budgets for the quarter.”

Gold Fields Limited (GFIOF), closed Thursday's trading session at $3.90, even for the day. The average volume for the last 60 days is 408 and the stock's 52-week low/high is $3.45/$4.80.

chart

Creative Medical Technology Holdings, Inc. (CELZ)

OTC Markets and MarketWatch reported on Creative Medical Technology Holdings, Inc. (CELZ), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Creative Medical Technology Holdings, Inc. (CMT) is a clinical stage stem cell company. Its focus is on Urology and Neurology utilizing stem cell treatments. CMT and its affiliate company, Creative Medical Health, Inc., have concentrated on regenerative medical solutions for unmet Urological and Neurological needs since 2011. The Company has a patent portfolio covering all treatments. CMT has its headquarters in Phoenix, Arizona.

The Company (via its own research and also collaborations with leading academic institutions) has acquired a pioneering stem cell (Amniostem), and developed proprietary protocols. It has also built an extensive intellectual property (IP) portfolio, developed complete treatment offerings for erectile dysfunction (ED), and launched a 40-patient trial for ED at UCLA. Moreover, CMT is making advances for treating stroke employing its newly acquired amniotic fluid-based stem cell.

Amniostem is Amniotic fluid derived stem cell. The Amniostem patent covers means to isolate, grow, and use amniotic fluid derived stem cells in a scalable and commercializable way. Amniostem therapy is a practical protocol for producing therapeutic quality stem cells starting from a small (1-5 ml) amniocentesis sample. Amniostem cells do not require matching with the recipient, as one size fits all.

CMT has its StemSpine™ initiative. This is a treatment designed to reverse the affects of atherosclerosis, which is the underlying disease that causes disc degeneration. CMT’s solutions include Caverstem™ for Erectile Dysfunction (ED).

The Company has an exclusive rights agreement with UCLA for US patent application # 14/508763, encompassing the use of stem cells for the treatment of male infertility. Additionally, CMT has filed US patent application number #62319753, covering the treatment of female sexual dysfunction utilizing stem cell and progenitor cell populations.

CMT announced in July 2017 preclinical data showing exosomes harvested from its patented Amniostem amniotic fluid stem cell, selectively inhibit growth of glioma brain cancer cells. Exosomes are nanoparticles generated by a variety of cells that are critically involved in intercellular communication. CMT earlier filed patents on the use of Amniostem derived exosomes for the treatment of stroke.

Last month, CMT announced the filing of a patent application utilizing a combination of a Food and Drug Administration (FDA) approved drug together with the patient's own bone marrow derived stem cells for the treatment of stroke. The patent, entitled "Autologous Bone Marrow Mononuclear Cells as a Substrate for Enhancement of Neuroregenerative Therapy", encompasses the use of the patient's bone marrow stem cells, together with an FDA approved drug, to stimulate the naturally occurring regenerative processes after certain kinds of strokes.

At present, CMT has two issued patents using the patient's own bone marrow stem cells covering disc regeneration #9,598,673, and erectile dysfunction #8,372,797. CMT recently reported completion of enrolment in its clinical trial for erectile dysfunction.

In addition, last month, CMT announced completion of the safety data analysis on 20 patients with pharmacologically-resistant erectile dysfunction treated with the Company's patented CaverStem™ procedure. The trial was sponsored by CMT.

The trial was conducted at the University of California Los Angeles Harbor Hospital/LA Biomed under Institutional Review Board (IRB) approval. Furthermore, an independent medical safety monitor was appointed to review the patient data for safety and feasibility of administering bone marrow derived stem cells into patients with erectile dysfunction.

Creative Medical Technology Holdings, Inc. (CELZ), closed Thursday's trading session at $0.0222, up 9.36%, on 108,131,254 volume with 2,041 trades. The average volume for the last 60 days is 41,623,501 and the stock's 52-week low/high is $0.0021/$0.55.

chart

Galaxy Gaming, Inc. (GLXZ)

Red Chip, SmallCapVoice, Marketbeat, TaglichBrothers, The Green Baron, FeedBlitz, and Stock Profile reported previously on Galaxy Gaming, Inc. (GLXZ), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Galaxy Gaming, Inc. is the world's largest independent developer, manufacturer, and distributor of casino table games and enhanced systems. The Company develops, manufactures, and distributes inventive proprietary table games, state-of-the-art electronic wagering platforms, and enhanced bonusing systems to land-based, riverboat, cruise ships, and online casinos globally. OTCQB-listed, Galaxy Gaming is based in Las Vegas, Nevada.

The Company has an installed base of its products on thousands of gaming tables located in hundreds of casinos. It sells its products primarily through its internal sales force, to casinos across North America, the Caribbean, the British Isles, Europe, and Africa. Galaxy Gaming also sells its products to cruise ships and internet gaming sites internationally.

The Company is the exclusive provider of SpectrumVision. This is a proprietary technology utilized to detect invisible markings on playing cards.

In addition, via its iGaming partner, Progressive Games Marketing Ltd., Galaxy Gaming licenses its proprietary table games to the online gaming industry. The Company’s games can be played online at FeelTheRush.com.

Furthermore, Galaxy Gaming is expanding its worldwide footprint through its partnership with WPT Enterprises, Inc. WPT Enterprises is the owner of the World Poker Tour.

In early April, Galaxy Gaming announced its results for the quarter and fiscal year ending December, 31, 2017. Financial highlights for Q4 2017 in comparison to Q4 2016 includes Revenue increasing 21 percent to $3,891K. Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) grew 26 percent to $1,465K. Pre-tax Income rose 4,392 percent to 412K. The Company had a Net Loss of $66K in comparison to Net Income of $112K.

Mr. Todd Cravens, Galaxy Gaming’s President and Chief Executive Officer, stated, “We finished the year well, with year-over-year revenue growth in the quarter of 21 percent. More importantly, revenue growth exceeded expense growth, resulting in year-over-year growth in adjusted EBITDA for the first time this year.”

Yesterday, Galaxy Gaming announced that it refinanced its existing indebtedness and that its Board authorized the repurchase of up to $1 million worth of the Company’s common stock.

Galaxy Gaming, Inc. (GLXZ), closed Thursday's trading session at $1.25, even for the day, on 12,900 volume with 8 trades. The average volume for the last 60 days is 21,341 and the stock's 52-week low/high is $0.51/$1.47.

chart

Nanophase Technologies Corp. (NANX)

Schaeffer’s, StockEgg, Wall Street Resources, SmarTrend Newsletters, Investment Contrarians, RedChip, Profit Confidential, CoolPennyStocks, BullRally, Stock Rich, HotOTC, Penny Invest, and Stealth Stocks reported on Nanophase Technologies Corp. (NANX), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Nanophase Technologies Corp. is a technology leader in nanomaterials and advanced nanoengineered products. The Company provides nanoengineered solutions for manifold industrial product applications. Nanophase assists its customers in succeeding, with proprietary and patent protected technologies. These technologies allow them to create unique products. Nanophase Technologies is based in Romeoville, Illinois. The Company’s shares trade on the OTCQB.

Nanophase Technologies’ products include Aluminum Oxide, Antimony Tin Oxide, Bismuth Oxide, Cerium Oxide, Iron Oxide, and Zinc Oxide. Nano metal oxides provide UV protection across plastics, exterior coatings, and textile applications. Infrared absorbing particles create high clarity, energy saving films and interlayers. The Company creates products with original performance attributes from two ISO 9001:2008 and ISO 14001 facilities.

Nanophase Technologies delivers commercial quantity and quality nanoparticles, coated nanoparticles, as well as nanoparticle dispersions in an array of media. The Company produces engineered nanomaterial products for use in an assortment of markets. These markets include Surface Finishing, Exterior Coatings, Personal Care, Plastics, Scratch Resistant Coatings, and Textiles.

Nanophase Technologies’ nano and submicron Aluminum Oxide imparts scratch resistance to coatings for wood, laminates, packaging, graphic arts, and electronics. Nano metal oxide technology improves the durability and capacity of zinc anode-based batteries.

Regarding nanoparticle surface treatment, Nanophase Technologies utilizes patented and proprietary particle coating technology to tailor the surface of the nanoparticles by discreetly encapsulating individual particles. The process can be used to impart a broad range of functionality to the particles that, in addition to helping to ensure success in the application, provides the Company’s customers with a considerable deal of flexibility in formulation with the nanoparticles. Nanophase Technologies can provide the products in dry powder or pre-dispersed formats.

Concerning nanoparticle production technology, the traditional and most customary manufacturing methods employed at the Company are plasma-based. The Physical Vapor Synthesis (PVS) and NanoArc® Synthesis (NAS) methods use transferred and non-transferred electric arcs to vaporize precursor materials. These are then carefully condensed to produce nanoparticles with desired properties. These methods have been used to produce simple and complex, multi-component mixed metal oxides.

Recently, Nanophase Technologies reported financial results for Q4 and Fiscal Year (FY) ended December 31, 2017. Revenue for FY 2017 was $12.5 million, in comparison to $10.8 million reported during the same period of 2016. The Net Loss for FY 2017 was $0.8 million, or a loss of $0.03 per share, versus a Net Loss of $1.3 million, or $0.04 per share, for the comparable period of 2016.

Revenue for Q4 was $2.6 million in 2017 and $2.4 million in 2016. Net Loss for the quarter was $0.2 million in 2017, or $0.01 per share, versus a Net Loss of $0.7 million, or $0.02 per share, for 2016.

Nanophase Technologies Corp. (NANX), closed Thursday's trading session at $1.17, down 1.68%, on 126,498 volume with 182 trades. The average volume for the last 60 days is 18,687 and the stock's 52-week low/high is $0.355/$1.30.

chart

BioRestorative Therapies, Inc. (BRTX)

Investor Ideas, Streetwise Reports, and ProActive Capital reported previously on BioRestorative Therapies, Inc. (BRTX), and today we report on the Company, here at the QualityStocks Daily Newsletter.

BioRestorative Therapies, Inc. is a life sciences company focusing on adult stem cell-based therapies for varied personal medical applications. The Company develops products and medical procedures using cell and tissue protocols, chiefly involving adult stem cells. BioRestorative Therapies has its corporate, administrative, and laboratory operations in Melville, New York.

BioRestorative’s aim is to become a leader in providing medical procedures utilizing cell and tissue protocols, mainly involving adult stem cells (non-embryonic), and allowing patients to undergo minimally invasive cellular-based treatments.

BioRestorative Therapies’ lead cell therapy candidate is BRTX-100. This product is formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow.

The Company’s products and medical procedures include brtxDISC™ (Disc Implanted Stem Cells), its Disc/Spine Program, and ThermoStem®, its Metabolic Program.

brtxDISC™ is an investigational non-surgical treatment for bulging and herniated lumbar discs. brtxDISC™’s intention is for patients who have failed non-invasive procedures and face the prospect of surgery.

ThermoStem® is a treatment using brown fat stem cells. ThermoStem® is under development for metabolic disorders. This includes diabetes and obesity.

BioRestorative Therapies is developing a cell-based therapy to target obesity and metabolic disorders utilizing brown adipose (fat) derived stem cells to produce brown adipose tissue (BAT). The intention of BAT is to mimic naturally occurring brown adipose depots, which regulate metabolic homeostasis in humans.

BioRestorative Therapies is the beneficiary of a patent granted for a licensed curved needle device (CND). The design of it is to deliver cells and/or other therapeutic products or material to a site having damage in need of facilitated repair.

In October of last year, BioRestorative Therapies announced that the Japan Patent Office issued the Company a Notice of Allowance on its patent application for a method of generating brown fat stem cells, related to its metabolic (ThermoStem®) program. Upon issuance in Japan, the final patent will allow for a method of isolating and differentiating a non-embryonic human brown adipose-derived stem cell into functional human brown adipocytes and a method of identifying compounds that modifies metabolic activity of human brown adipocytes.

This technology is applicable for potential therapeutic uses for treating a broad spectrum of degenerative and metabolic disorders. This includes, but is not limited to, diabetes, obesity, hypertension as well as cardiac deficiency. This will be the third patent issued for BioRestorative Therapies’ brown fat metabolic technology.

BioRestorative Therapies, Inc. (BRTX), closed Thursday's trading session at $3.00, up 7.53%, on 8,600 volume with 15 trades. The average volume for the last 60 days is 2,166 and the stock's 52-week low/high is $2.50/$4.75.

chart

RegeneRx Biopharmaceuticals, Inc. (RGRX)

PennyStockProphet, Penny Pick Finders, Planet Penny Stocks, Buzz Stocks, Stock Onion, Stock News Now, TopPennyStockMovers, and SmarTrend Newsletters reported earlier on RegeneRx Biopharmaceuticals, Inc. (RGRX), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

OTCQB-listed, RegeneRx Biopharmaceuticals, Inc. is a clinical-stage drug development company. It centers on tissue protection, repair, and regeneration with a wide-ranging portfolio of product candidates for first-in-class therapeutic peptides. The Company’s mission is to research and develop novel pharmaceuticals, which protect and repair tissue and organ damage caused by disease, trauma, or other pathology. RegeneRx Biopharmaceuticals is headquartered in Rockville, Maryland.

The Company holds manifold issued patents or filed patent applications worldwide to enable and protect numerous indications and applications for its product candidates. At present, RegeneRx has three drug candidates in clinical development for ophthalmic, cardiac, and dermal indications.

Furthermore, the Company has three active strategic licensing agreements in the U.S, China, and Pan Asia (Korea, Japan, and Australia, among others). In addition, RegeneRx has patents and patent applications covering its products in many nations globally.

RegeneRx Biopharmaceuticals is concentrating on moving three distinct Tβ4-based drug candidates through the clinic. These are RGN-137, RGN-259, and RGN-352. RGN-137 is a topical gel formulation of the peptide Tβ4. The Company is developing this as a novel treatment to expedite dermal healing. RGN-137 is a Tβ4-based dermal gel formulation undergoing development for epidermolysis bullosa, which is a rare skin condition.

RegeneRx Biopharmaceuticals is focusing on the development of Thymosin beta 4 (a novel therapeutic peptide), for tissue and organ protection, repair and regeneration. RGN-259, its TB4-based ophthalmic drug candidate, has been designated an orphan drug for the treatment of neurotrophic keratopathy (NK), which is a primary focus of RegeneRx’s clinical development efforts in the U.S.

RegeneRx is also developing RGN-352. RGN-352 is its TB4-based injectable. This is a Phase 2-ready drug candidate designed to be administered systemically to prevent and repair cardiac damage resulting from heart attacks and central nervous system tissue damage associated disorders. These include peripheral neuropathy, multiple sclerosis and traumatic brain injuries - including stroke.

This past November, RegeneRx Biopharmaceuticals announced that Thymosin beta 4 (Tβ4), the active ingredient in RGN-259, a preservative-free ophthalmic eye drop, was the subject of a Keynote Address at the 5th International Symposium of Thymosins in Health and Disease in Washington, DC. The presentation was given by Dr. Gabriel Sosne, an award-winning clinician scientist, Associate Professor in Ophthalmology and Anatomy and Cell Biology at Wayne State University School of Medicine, and a clinician at the Kresge Eye Institute in Detroit, Michigan.

RegeneRx Biopharmaceuticals, Inc. (RGRX), closed Thursday's trading session at $0.22, up 3.77%, on 70,178 volume with 12 trades. The average volume for the last 60 days is 52,503 and the stock's 52-week low/high is $0.139/$0.38.

chart

iAnthus Capital Holdings, Inc. (ITHUF)

InvestorsHub, Daily Marijuana Observer, Stockhouse, MarketWatch, and OTC Markets reported on iAnthus Capital Holdings, Inc. (ITHUF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

iAnthus Capital Holdings, Inc. is a provider of capital investment and management services to licensed cannabis cultivators, processors, and dispensaries across the U.S. The Company, through its 100 percent owned subsidiary, iAnthus Capital Management, LLC, delivers a total solution for financing and managing these enterprises. iAnthus supports a diverse portfolio of cannabis industry investments. iAnthus Capital Holdings has its head office in New York, New York. The Company also has a Toronto, Ontario office.

iAnthus Capital Holdings owns, operates, and partners with licensed cannabis operations throughout the U.S. The Company provides an innovative combination of capital and practical operating and management expertise.

iAnthus creates agreements that establish valuable partnerships. It has developed strategic partnerships with best-in-class industry-sector leaders in dispensary operations, commercial-scale cannabis cultivation, regulatory law, and the science of cannabis product formulation and testing.

The Company’s present portfolio includes Grassroots Vermont; Mayflower Medicinals, Inc.; Organix, Breckenridge Colorado; and R. Greenleaf Organics.

iAnthus Capital Holdings announced this past January that Mayflower Medicinals received its final certificate of registration (FCR) and certificate of occupancy (CO) from Massachusetts regulators and local officials on December 28, 2017 to begin cannabis cultivation and production operations at its facility in Holliston, Massachusetts.

Mayflower Medicinals is a non-profit Massachusetts corporation. It has received two provisional licenses to operate Registered Marijuana Dispensaries (RMDs) in Massachusetts, with a third RMD application pending before the Massachusetts Department of Public Health (DPH).

iAnthus earlier acquired 80 percent of Pilgrim Rock Management, LLC. Pilgrim Rock is an affiliated management and services company. It will provide intellectual property (IP) licensing, professional and management services, real estate and equipment leasing, and certain other services to Mayflower Medicinals, pursuant to a services agreement between Pilgrim Rock and Mayflower effective as of January 1, 2018.

iAnthus Capital Holdings has acquired, via merger and acquisition transactions, largely all of the assets of GrowHealthy Holdings, LLC and certain related subsidiaries. This Acquisition completes iAnthus Capital’s full-scale entry into the fast expanding Florida medical cannabis market. iAnthus previously acquired about 6 percent of GrowHealthy in a preferred share purchase in October of last year.

GrowHealthy Holdings has started delivery to patients in Florida. It has signed a lease for a dispensary location in Orlando, Florida.

In February, iAnthus Capital Holdings announced that it acquired Citiva Medical, LLC (Citiva NY), which holds one of the ten vertically integrated medical marijuana "Registered Organization" licenses issued by New York State, and Citiva, LLC (Citiva USA and, together with Citiva NY, Citiva), the owner of certain regulated cannabis industry assets and intellectual property (IP). With the closing of the Citiva acquisition, iAnthus' regulated cannabis industry operations now cover six states.

Last week, iAnthus Capital Holdings announced the completion of its acquisition of the remaining 20 percent of Pilgrim Rock Management, LLC.

iAnthus Capital Holdings, Inc. (ITHUF), closed Thursday's trading session at $3.1602, up 1.91%, on 65,484 volume with 131 trades. The average volume for the last 60 days is 159,307 and the stock's 52-week low/high is $1.325/$5.0802.

chart

El Capitan Precious Metals, Inc. (ECPN)

HotOTC, StockEgg, StockRich, TopPennyStockMovers, SmallCapVoice, PennyInvest, CoolPennyStocks, AllPennyStocks, PennyTrader Publisher, BullRally, MadPennyStocks, PennyStockVille, and OTCPicks reported on El Capitan Precious Metals, Inc. (ECPN), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

El Capitan Precious Metals, Inc. is a mining company based in Scottsdale, Arizona. It mainly engages in the mining of precious metals and other minerals. The Company chiefly holds interest in the El Capitan gold-silver property situated close to Capitan, New Mexico, in Lincoln County. El Capitan Precious Metals’ principal asset is its wholly-owned subsidiary El Capitan, Ltd., an Arizona corporation.

The El Capitan, Ltd. subsidiary holds the 100 percent equity interest in the El Capitan property. The Company’s primary objective is the sale of the El Capitan property.

The El Capitan deposit has been known as a potential iron ore resource for numerous decades. The El Capitan deposit has a near-surface, pervasive nature. All of this takes place above the regional water table. This provides the potential for a low mining cost and a long life operation.

El Capitan Precious Metals owns 3,840 acres of mining property in Lincoln County. This includes 80 acres of patented and 3,760 acres of leased property. These include 188 mining claims. The El Capitan property encompasses 354 Bureau of Land Management (BLM) lode claims and four patented claims.

El Capitan Precious Metals has enhanced its relationship with Logistica US by way of an agreement under which El Capitan will provide to Logistica concentrated ore to their specifications at the mine site. Logistica will transport, process, as well as refine the precious metals concentrates to sell to precious metals buyers. The agreement is in addition to and complements the previously announced agreement for the sale of iron ore for use in construction.

In December 2017, El Capitan Precious Metals announced that it entered into an agreement with a refiner that will buy, refine, and sell the hyper-concentrates generated by the pilot plant. Moreover, the Company reported that the refiner has spent a considerable amount of time with its contract miner at the pilot plant and at the mine site.

This past January, El Capitan Precious Metals announced that an agreement was executed in December 2017 for the sale of the Company’s precious metal hyper-concentrates. El Capitan Chairman and Chief Executive Officer, Mr. John F. Stapleton reported that El Capitan reached a final agreement with a buyer and executed a Purchase Agreement for all remaining hyper-concentrates produced by the Pilot Plant from the concentrate materials stored at the bonded warehouse in Tucson, Arizona.

The sale represents the last El Capitan Pilot Program activity. It successfully completes the objectives of the Pilot program.

This month, El Capitan Precious Metals reported a breach of contract by the buyer of concentrates. The Company reported that it was informed on March 30, 2018, that the contracted buyer to purchase and process the concentrates from El Capitan Precious Metals decided not to process the material. Instead, the contracted buyer is offering to ship the material back to El Capitan Precious Metals.

El Capitan is investigating the matter. The Company said it will take all necessary and proper steps to pursue civil and criminal litigation of the matter, if appropriate upon further investigation, upon the material being returned. El Capitan Precious Metals will provide further details at the 2018 Shareholder Meeting scheduled for Wednesday, May 23, 2018 in Scottsdale, Arizona.

El Capitan Precious Metals, Inc. (ECPN), closed Thursday's trading session at $0.03, up 0.33%, on 105,000 volume with 5 trades. The average volume for the last 60 days is 277,322 and the stock's 52-week low/high is $0.0264/$0.085.

chart

ProtoKinetix, Inc. (PKTX)

SmallCapVoice, TopPennyStockMovers, 777 Stocks, Breaking Bulls, InsideBulls, Stock Market News Alert, HotOTC, OTCReporter, Stock Rich, PennyStockAce, Stockpalooza, SuperBirdStocks, WallStAlerts, Willy Wizard, Pick Alerts, Penny stock Profitz, AllPennyStocks, Penny Invest, CoolPennyStocks, StockEgg, and Round Up the Bulls reported earlier on ProtoKinetix, Inc. (PKTX), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, ProtoKinetix, Inc. is a molecular biotechnology company. It has developed and patented a family of hyper stable, potent glycopeptides (Anti-Aging GlycoPeptide - AAGP™), which enhance engraftment and protection of transplanted cells used in regenerative medicine. Because of the anti-inflammatory effect of AAGP™ molecules, ProtoKinetix is now targeting the direct treatment of diseases that have a major inflammatory component. The Company’s molecule, AAGP™, is an antifreeze glycopeptide. It imitates a naturally occurring glycoprotein found in Arctic fish. ProtoKinetix is based in Marietta, Ohio.

The Company’s AAGP™ molecule is helping to considerably improve the efficacy of Cell Transplant Treatments for diabetes. ProtoKinetix has extensive patent protection for its portfolio of anti-aging glycopeptides. The Company’s anti-aging glycopeptide, trademarked AAGP™, is a small (580.96 Daltons), stable, synthetic replica of the larger (>2,600 Daltons), less stable AFGP that has been found to have protective properties in nature.

The small size of AAGP™ enables it to penetrate cells and allows it to pass through cell and capillary junctions in vivo. Also, its bioactivity at a range of pHs (5.3-10.3) and temperatures (-196°C to 22°C) and efficiency at concentrations (1mg/ml) is well under its toxic dose (50mg/ml). This makes it a candidate to enter the next stages of translational research.

In March 2017, ProtoKinetix announced the start of a Phase 1 first-in-human clinical trial of AAGP™ PKX-001 treated islet cells used together with the Edmonton Protocol for the treatment of Type 1 diabetes. The first patient was treated under the protocol.

In May 2017, ProtoKinetix announced that it completed the first year of retinal replacement therapy trials on animals. It said that the results are encouraging enough to proceed to a second phase of testing. The cells treated with AAGP™ showed an improvement on cell survivability and viability in comparison to the untreated cells. Continuing testing is now taking place to determine if these transplanted cells are fully functioning.

ProtoKinetix and Proactive Immune Sciences entered into a joint research collaboration. The goal of the research is to test the effect of the patented anti-aging glycopeptide AAGP™ on the immune cell cryopreservation protocols used by Proactive Immune Sciences.

Recently, ProtoKinetix, provided a scientific update on immune cell banking and functions relevant to immunotherapy utilizing AAGP™ in collaboration with Proactive Immune Sciences. Earlier in 2017, Proactive started a research program that used an anti-aging glycopeptide (AAGP™) produced by ProtoKinetix that, among other uses, has shown the potential to benefit various cells during cryopreservation.

In the research program, Proactive Immune Sciences is investigating whether the AAGP™ produced by ProtoKinetix improves survival and function of cryopreserved immune cells through assessment of the effect of AAGP™ on cryopreserved immune cell viability and functionality. Proactive Immune Sciences stores (banks) immune cells, while people are healthy. This is for them to use later in life should they contract cancer or have other immune system related diseases.

ProtoKinetix, Inc. (PKTX), closed Thursday's trading session at $0.05, up 17.65%, on 39,022 volume with 5 trades. The average volume for the last 60 days is 43,702 and the stock's 52-week low/high is $0.03/$0.0899.

chart

The QualityStocks Company Corner

Zenergy Brands, Inc. (ZNGY)

The QualityStocks Daily Newsletter would like to spotlight Zenergy Brands, Inc. (ZNGY).

Zenergy Brands, Inc. (OTCQB: ZNGY), the nation's leading next-generation utility announced today the soft launch of its new business development initiative entitled the Zenergy Associate Program.

Zenergy Brands, Inc. (ZNGY) is the nation’s leading next-generation energy and technology company operating in the emerging smart energy, conservation, and utility industries. Headquartered in Texas, Zenergy provides an entire suite of conservation-based products and services that enable clients to achieve sustainability goals, reduce carbon emissions and improve their bottom line. The company’s cutting-edge Zero Cost Program™ reduces utility expenses by 20 percent to 60 percent by offering energy conservation, smart controls, and efficiency-based products and services to residential, commercial, industrial and municipal end-use customers.

The Zero Cost Program™ is a financing mechanism that allows customers to reduce water, natural gas and electricity expenses by implementing proven conservation technologies at no out-of-pocket cost. The Zero Cost Program™ enriches businesses by immediately reducing energy consumption through the use of smart controls, building automation, LED lighting solutions, refrigeration optimization, efficient water systems, EC motor controls, demand-side management and load factor correction.

A unique Managed Energy Services Agreement (“MESA”) allows a portion of these utility savings to be retained by Zenergy’s partner financing the upgraded, retrofit equipment and installation costs until a specified repayment period ends. After that, clients reap all the financial rewards of the technologies implemented, which Zenergy estimates should range between 25 percent and 45 percent of total utility costs.

Residential customers seeking cost-effective energy savings can also choose from a suite of “Smart Home” products including home automation, security monitoring, and energy conservation services that can be controlled 24/7 from the comfort and convenience of their smartphones or internet-connected smart devices. Zenergy’s residential program offers partnership opportunities for homebuilders and residential, multi-family real estate developers to provide smart home technologies to high-end customers.

Zenergy Brands’ acquisition of Enertrade Electric LLC, a fully operating, licensed Texas-based Retail Electric Provider (REP), further increases the company’s value proposition. Zenergy CEO Alex Rodriguez said this new subsidiary adds an essential complementary service to the company’s suite of smart energy products and services.

“Since our founding, our vision has been to converge smart controls (home and building automation) with energy conservation and retail energy to deliver the comprehensive smart energy service to customers,” Rodriguez said.

On a global scale, residential and commercial buildings account for nearly 45 percent of the world’s total energy consumption. Improving the energy efficiency of these homes and buildings is often a more affordable way to reduce harmful gas emissions while minimizing the need for new energy production. According to Navigant Research, global revenue for energy-efficient commercial building retrofits alone is expected to grow from $71.4 billion in 2016 to $100.8 billion in 2025. At the same time, the energy-efficient devices market is expected to reach a market size of $908 billion by 2022. Increasing demands for reduction in energy consumption and greenhouse gas emissions along with concerns over climate change are contributing factors driving the market’s overall growth.

Zenergy Brands, Inc. (ZNGY), closed the day's trading session at $0.0125, up 31.58%, on 2,396,886 volume with 96 trades. The average volume for the last 60 days is 3,027,115 and the stock's 52-week low/high is $0.0027/$0.045.

Recent News

chart

Hammer Fiber Optic Holdings Corp. (OTCQB: HMMR)

The QualityStocks Daily Newsletter would like to spotlight Hammer Fiber Optic Holdings Corp. (HMMR).

Hammer Fiber Optic Holdings Corp. (OTCQB:HMMR), a telecommunications company investing in the future of wireless technology, announces it has engaged the corporate communications expertise of NetworkNewsWire.

Hammer Fiber Optic Holdings Corp. (HMMR), with headquarters in New Jersey, is a telecommunications company investing in the future of wireless technology. The company’s holdings include Hammer Fiber Optic Investments, Ltd., D/B/A Hammer Fiber, an Internet Service Provider (ISP) that offers internet, voice, video and data services in New Jersey as well as carrier services in Philadelphia and New York. Hammer Fiber serves residential and small business markets with high-capacity broadband, voice and video through direct fiber as well as its wireless fiber platform – Hammer Wireless® AIR technology.

Hammer Fiber recently completed the initial development phase of its advanced LTE fixed wireless system, which was designed and built upon its successfully deployed wireless technology suite. The expansion allows Hammer Fiber to add ultra-high capacity cellular broadband applications to its product portfolio including wholesale services such as backhaul support for cellular network operators. Designed to complement Hammer Fiber’s core business of home residential service, the company expects this latest innovation to help position Hammer Fiber as a leader in future 5G technology. The company intends to leverage the Fixed LTE system in conjunction with its already deployed Fixed Wireless DOCSIS 3.1 system to deliver on one of its core promises, to deliver high capacity broadband to markets across the country at dramatically lower cost than traditional wireline methods, including fiber. Live field testing of the new system begins in early 2018 in the U.S. with service availability to follow later in the year.

Hammer Fiber has also expanded its IaaS (Infrastructure-as-a-Service) cloud services to include support for the cryptocurrency and blockchain industry. Interested companies will be able to host their products over Hammer Fiber’s robust and modern server infrastructure, fiber network architecture and data center presence in some of the most secure locations in the New York, New Jersey and Philadelphia regions. Hammer Fiber’s servers feature best-in-class computing power, designed to allow enterprise businesses to reap the benefits of utilizing a cloud-based system without the massive cost of establishing or maintaining a corporate data center.

“Distributed architecture infrastructure, such as those utilized by blockchain entities mining cryptocurrencies or other new vertical markets utilizing blockchain technology, are growing exponentially and we are poised to fulfill a critical but fundamental need of this explosive new industry,” said Mark Stogdill, CEO of Hammer Fiber. “The distributed ledger architectures that blockchains are built on require secure and robust data processing networks, highly scalable power generation and a reliable fiber optic backbone infrastructure linking up data centers worldwide for them to exist, and that is what we at Hammer Fiber do really well.”

Hammer Fiber seeks to achieve its vision by employing an extremely qualified group of business professionals with diverse backgrounds and successful track records from a variety of related industries. HMMR’s seasoned leadership team combines startup expertise with a consummate understanding of the regional competitive telecommunications landscape in sales, marketing, engineering, construction and business development.

Hammer Fiber Optic Holdings Corp. (HMMR), closed the day's trading session at $2.72, even for the day, on 1,973 volume with 15 trades. The average volume for the last 60 days is 6,658 and the stock's 52-week low/high is $2.72/$48.00.

Recent News

chart

EVIO, Inc. (EVIO)

The QualityStocks Daily Newsletter would like to spotlight EVIO, Inc. (EVIO).

EVIO, Inc. (OTCQB:EVIO), today announced that Singular Research has initiated analyst coverage on the Company. Singular Research is a trusted supplier of independent, single-source research on small-to-micro cap companies. The analyst report may be viewed on the OTC Markets Group website.

EVIO, Inc. (EVIO), via the EVIO Labs division, is the nation’s leading provider of accredited analytical testing, scientific research and advisory services to the regulated cannabis industry. EVIO Labs provides state-mandated ancillary services that are required to ensure the safety and quality of the nation’s cannabis supply. EVIO Labs has performed over 50,000 tests during the past two years and grown from one laboratory in Oregon to nine labs spanning California, Oregon, Colorado, Massachusetts and Florida.

EVIO Labs is driving the cannabis testing industry by providing clients nationwide with consistent high-quality cannabis analytical services backed by quality control assurances. The company also provides advisory services that help cannabis producers and retailers enhance production processes, achieve regulatory compliance and meet quality goals.

EVIO Labs is on track to open 18 laboratories by the end of 2018 at locations around the United States. The Oregon-based company provides analytical services that include testing cannabis and industrial hemp flower, extracts and infused products. The labs specialize in performing the following tests:

  • Cannabinoid analysis, which properly characterizes the many primary cannabinoids found in cannabis including THC, CBD, and several other cannabinoids.
  • Terpene analysis, which identifies the aromatic compounds of the plant (terpene), which can help identify the therapeutic potential of a cannabis flower or extract.
  • Moisture content and water activity, which measure the moisture levels of dried cannabis and are indicators of microbiological growth potential.
  • Pesticide residue analysis of over 100 different pesticides, herbicides, fungicides, growth regulators and other agrochemicals that may be present on cannabis.
  • Detection of harmful residual solvents left behind in the cannabis extract production process.
  • Microbial testing screen for bacterial and fungal contamination in cannabis and cannabis-infused products.
  • Detection of heavy metals including lead, cadmium, mercury, and arsenic.

EVIO Labs is rapidly becoming the nation’s leading cannabis biotechnology company. Led by a management team with extensive experience in designing and rolling out successful business ventures, product research and development, regulatory and compliance protocols, medical cannabis cultivation, production and analytical chemistry techniques, EVIO Labs is prepared to take advantage of today’s fastest growing industry.

EVIO, Inc. (EVIO), closed the day's trading session at $1.64, up 3.80%, on 134,321 volume with 201 trades. The average volume for the last 60 days is 77,492 and the stock's 52-week low/high is $0.47/$2.70.

Recent News

chart

Zenosense, Inc. (ZENO)

The QualityStocks Daily Newsletter would like to spotlight Zenosense, Inc. (ZENO).

The global point-of-care (POC) diagnostics market is forecast to grow at a CAGR of 10 percent, from $23.71 billion in 2017 to $38.13 billion in 2022, according to a recent Research and Markets report (http://nnw.fm/o0fNq). Zenosense, Inc. (OTC: ZENO) is well positioned to capitalize on the projected growth in this market through the development and commercialization of its MIDS Cardiac device, a game changing POC technology.

Zenosense, Inc. (ZENO) (the “Company”) is a healthcare technology developer that participates in transformational, disruptive medical diagnostic projects; particularly handheld devices used at the Point of Care which are displacing slow and expensive laboratory tests.

Zenosense is primarily focused on the development and commercialization of MIDS Cardiac™ through the Company’s joint venture ownership in MIDS Medical Limited (“MML”). MIDS Cardiac is in development as a cost-effective, handheld Point of Care (“POC”) diagnostic device and disposable test strip for the early, rapid detection of suspected acute myocardial infarction (“AMI”, or “heart attack”).

Identification of very low levels of cardiac markers can significantly accelerate critical triage, diagnosis, treatment and disposition of patients reporting chest pain. Cardiac troponin is well documented as the preferred biomarker for diagnosis of AMI, with evidence continuing to demonstrate that high sensitivity troponin is the most powerful prognostic biomarker for the assessment of cardiovascular risk in the general population. However, highly sensitive troponin assays are currently available only on state of the art, central laboratory analyzers. These analyzers are extremely expensive, not generally available at the POC and slow to turnaround results (typically 60 minutes) when time is critical.

True, high-sensitivity devices are not available in smaller handheld devices at the POC, where they are most needed. This is because the optical detection systems generally used in central laboratory analyzers cannot be effectively miniaturized.

MIDS Cardiac uses the patented MIDS technology platform, exclusively available to MML. Instead of using conventional optical detection, MIDS can detect and quantify assay beads nano-magnetically. This means it can be incorporated in a small device expected to achieve highly sensitive detection levels, which can support true high sensitivity cardiac biomarker tests in emergency settings, at the POC.

Harnessing world-class expertise, the MML laboratory is located at the prestigious Sci-Tech Daresbury campus in the U.K., internationally recognized for leading-edge, scientific research and commercial development. MML has the sole rights to the MIDS technology platform, which is protected by patent applications already granted in China and the USA, and applications now in the national phase in all other key geographic areas.

MIDS Cardiac aims to provide a single troponin I or T test within 3 minutes and three panel assay (additional cardiac biomarkers) on a disposable test strip within 8 minutes, using a hand-held device costing a fraction of the price of laboratory analyzers.

MIDS Cardiac should only require a pin prick of blood for a single assay test carried out on an easy-to-use, disposable microfluidic test strip. MIDS Cardiac is being designed to be operated quickly by minimally trained personnel, producing a simple to interpret result in emergency settings, even in the back of an ambulance.

Initial testing of the electronic and microfluidic components of the MIDS Cardiac “Hybrid Strip” system was completed in November 2017. The Hybrid Strip system used for development testing aims to replicate as closely as possible a fully integrated Lab on Chip MIDS test strip set-up. Development testing was conducted on both the assembled hybrid unit and its electronic and microfluidic components separately, focusing mainly on the electronics of the magnetic sensing system.

Testing revealed that a variety of brands and sizes of commercially available assay beads could be magnetically detected in very low quantities, including samples of beads that were previously undetectable. In several instances, the current “limit of detection” appeared to already be at or near to the range advised by MML’s assay consultants as suitable for a high sensitivity troponin assay.

Dr. Nasser Djennati, MML’s Managing Director and Chief Scientific Officer, said; “These results come in at the very high end of detection expectations, even at this Hybrid Strip stage. As we move forward into true Lab on Chip construction, I expect detection levels to improve further still.”

Cardiovascular disease is the leading cause of death in the western world, accounting for more than 17 million deaths in Europe and the United States alone. Nearly 20 million patients each year visit an emergency room with reports of chest pain, with hundreds of millions spent on unnecessary admissions to the hospital. Zenosense Inc. is confident MIDS Cardiac will deliver unparalleled levels of accuracy, speed, reliability, ease of use and cost savings, making it the future device of choice for hospitals, emergency rooms, medical practitioners, paramedics and in low-resource settings.

The MIDS technology is also seen as having a far wider application, with the platform being capable of performing Point of Care immunoassay tests for a vast array of common healthcare concerns, a market projected to be worth $23.7 billion per year worldwide by 2019. The medical testing market as a whole is projected to be worth $53.34 billion by 2021. Zenosense believes the MIDS technology could be the most significant advance in diagnostic testing services in decades.

Zenosense, Inc. (ZENO), closed the day's trading session at $0.42495, up 1.18%, on 84,062 volume with 36 trades. The average volume for the last 60 days is 101,710 and the stock's 52-week low/high is $0.2021/$0.895.

Recent News

chart

Sunniva, Inc. (CSE: SNN) (OTCQX: SNNVF)

The QualityStocks Daily Newsletter would like to spotlight Sunniva, Inc. (SNNVF).

NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company for business, today announces the audio version of Sunniva Inc. (CSE:SNN) (OTCQX:SNNVF) recent press release titled “Sunniva Inc. to Delay Earnings Release Until April 30, 2018.” To hear the Sunniva Inc. AudioPressRelease (APR) version, visit: http://nnw.fm/p6fEC. To read the original press release, visit: http://nnw.fm/Ie6Eq.

Sunniva, Inc. (CSE: SNN) (OTCQX: SNNVF) is a vertically integrated medical cannabis company operating in the world’s two largest cannabis markets – Canada and California – committed to delivering safe, consistent, high-quality products and services. Sunniva operates through its wholly owned subsidiaries: Sunniva Medical Inc., CP Logistics, LLC, Natural Health Service Ltd., and Full-Scale Distributors, LLC. Sunniva’s vision is to become the lowest cost, highest quality cannabis producer in the markets it serves by building large scale purpose-built cGMP-compliant greenhouses, offering best quality assurance with cannabis products free from pesticides, providing better patient and doctor access to cannabis education, and sourcing better therapeutic delivery devices.

The company is establishing sophisticated distribution channels, including Sunniva’s ownership of Natural Health Services cannabis clinics in Canada with over 95,000 active patients, to purchase the significant quantities of high quality Sunniva-branded and Sunniva private-labeled cannabis products.

Sunniva is an ancient English name which means, “Gift of the Sun.” Sunniva’s team of horticulturists, scientists and engineers is helping to set best practices for the industry, believing that sun-grown, solar-powered cultivation is the most sustainable and cost-effective way to grow high-quality, premium cannabis.

The Sunniva Family includes:

CP Logistics, LLC

Through its subsidiary, CP Logistics LLC, Sunniva is developing Sunniva Campus, a state-of-the-art, purpose-built greenhouse facility in Cathedral City, California. This modern purpose-built, agri-technology greenhouse will adhere to the Current Good Manufacturing Practice (cGMP) regulations that assure proper design, monitoring and control of manufacturing processes and facilities.

Phase 1 of the project includes a fully funded 325,000 square foot greenhouse capable of producing 60,000 kg per year of dry cannabis at capacity with operations commencing Q3 2018. Approximately 30 percent of initial total production will be converted into oils and extracts. Phase 2 is expected to increase the greenhouse by 165,000 square feet and grow production by about 40,000 kg per year.

These uniquely sealed greenhouses are designed to deploy custom, automation assembly line cultivation processes at a large scale. Energy consumption will be reduced while utilizing the energy of the sun and microclimatic controls to provide precise growing conditions. The greenhouse will recirculate air for more efficient climate control, and the company’s Integrated Pest Management System is designed to ensure every plant grown is certified clean and free of all contaminants and pesticides.

Sunniva Medical Inc.

Sunniva Medical Inc. is designing and preparing to break ground on the Sunniva Canada Campus encompassing 700,000 square feet of purpose-built cGMP greenhouse facilities in the Okanagan Valley, British Columbia. The total campus is expected to produce 100,000 kg of premium medical cannabis a year plus additional trim used for extraction. This facility will produce pesticide-free products and will convert trim to extracted products such as cannabis oil that can be used for drug delivery formats such as capsules, dissolvable strips, vaporization cartridges, tinctures and creams.

Sunniva and Canopy Growth Corporation (“Canopy Growth”) recently announced a large take or pay supply agreement. Under the terms of the agreement, Canopy Growth will purchase up to 45,000 kilograms of dried cannabis annually commencing Q1 2019, which includes the distribution of Sunniva branded products. Sunniva Medical is a late-stage applicant under Canada’s ACMPR and is in the final review stage of the process.

Natural Health Services Ltd.

Natural Health Services (“NHS”) owns and operates a network of eight medical clinics in Canada specializing in medical cannabis under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). NHS connects licensed producers to their 21 physicians and patients with its proprietary SPARK software which utilizes a software-as-a-service revenue model. To date, there are 27 integrated licensed producers utilizing the SPARK software.

In-house physicians specializing in the endocannabinoid system provide expert consultation, education and recommendations for targeted phytoceutical remedies and wellness plans to improve the quality of life for all patients. NHS enjoys a long-term relationship with patients due to the quality of its physician-patient experience. A rapidly expanding NHS cannabis clinic network serves 94,000 active patients in Canada. NHS has also initiated a pilot program with a national pharmacy chain to aggregate more patients.

Full-Scale Distributors, LLC

Full-Scale Distributors, LLC is an industry leading provider of custom, private-label vaporizers through its brand, Vapor Connoisseur. The company currently serves the needs of over 80 top brands in the North American marketplace. Vapor Connoisseur is recognized for its high quality and innovative therapeutic delivery devices. Products are tailored to client needs, ensuring both safety and reliability.

Sunniva’s highly experienced management team is building partnerships with leading scientists, universities and clinical trial groups to deliver proprietary cannabis formulations to a broad spectrum of health ailments and conditions. These global partners require cGMP-certified facilities for the processing and manufacturing of cannabis products. Sunniva is committed to providing safe, pesticide-free, high quality, reproducible cannabis medicines.

Leading Sunniva is co-founder, chairman and CEO Dr. Anthony (Tony) Holler. He is the former CEO and founder of ID Biomedical, which was acquired in 2005 for $1.7 billion by GlaxoSmithKline. He is also the former chairman of Corriente Resources Inc., which was sold for approximately $700 million to CRCC-Tongguan Investment Co. Holler is currently chairman of CRH Medical Corporation, a public company trading on the TSX and NYSE. His expertise includes strategic planning, mergers and acquisitions and financing with a singular focus on increasing shareholder value.

Holler is joined by co-founder Leith Pedersen, who serves as president of Sunniva. Pedersen is the former owner and CEO of Vida Wealth Management Bahamas and was a former investment advisor at Canaccord Wealth Management. He is a former partner and director at JF Mackie and Company, an independent brokerage firm in Calgary, Alberta, that managed capital in excess of $2 billion for high net worth clients. Pedersen’s expertise is in corporate strategy, financing and mergers and acquisitions.

Sunniva, Inc. (SNNVF), closed the day's trading session at $6.50889, off by 2.12%, on 34,144 volume with 99 trades. The average volume for the last 60 days is 38,973 and the stock's 52-week low/high is $6.035/$16.00.

Recent News

chart

Epazz, Inc. (EPAZ)

The QualityStocks Daily Newsletter would like to spotlight Epazz, Inc. (EPAZ).

Epazz, Inc. (OTC: EPAZ), a leading provider of blockchain cryptocurrency mobile apps and cloud-based business software solutions, announced today that the ZenaPay Blockchain Bitcoin wallet will release its next version in June. This release supports Bitcoin Cash and Segwit on Play store. ZenaPay already supports Bitcoin and Ethereum.

Epazz, Inc. (EPAZ) is a leading provider of blockchain cryptocurrency mobile apps and cloud-based business software solutions that specializes in providing customized web applications to the corporate world, higher education institutions and the public sector. The company’s strategic expansion into the investment fintech software space can be seen in the recent acquisition of the android app CryptoFolio, which securely tracks and manages Bitcoin and Altcoin portfolios. Epazz, Inc., which acquired the software rights, source code and user base of CryptoFolio, plans to add additional cryptocurrencies and languages to the app, along with an iOS version to attract more users.

Epazz also offers ZenaPay Bitcoin wallet, which has been downloaded more than 10,000 times since its launch on the Play Store. A subsidiary of Epazz, ZenaPay is a financial technology company that offers a unique, secure and reliable Bitcoin payment app, allowing consumers to acquire Bitcoin at the point-of-sale. The consumer can then use this digital currency to make a purchase with ease. The CryptoFolio business model provides free features to attract users and then allows users to purchase additional features from $1.99 to $5.99 each. CryptoFolio is a great add-on app for ZenaPay, and future versions of CryptoFolio will include an option to download ZenaPay.

“We are starting 2018 with ZenaPay on both major mobile apps’ platforms,” said Shaun Passley, PhD, CEO and founder of Epazz. “We are in the processing of developing new blockchain technology which will introduce an additional source of revenue streams for our company.”

Epazz technology makes it easy to convert legacy systems into cloud business process software, for which the company then charges an annual subscription fee. Epazz has acquired 11 software companies that have converted or are in the process of converting their legacy software products to cloud software using Epazz technology. Epazz then markets the new cloud-based solutions to new and existing customers.

Epazz’s unique BoxesOS™ applications can create virtual communities for enhanced communication, provide information and content for decision-making, and create a secure marketplace for any type of commerce. Epazz has also filed a provisional patent for its new blockchain smart legal contract technology that reduces fraud in business transactional contracts. The technology allows for a transactional contract to become a living contract that is tracked and traced; it also verifies that a section of terms within a contract are followed and that all parties of an agreement obey the terms of the contract.

“Blockchain-based technology is the future of the Internet,” Passley said. “Epazz will add blockchain technology to all of our products in the coming months using our blockchain cloud platform, BoxesOS. The company has been working with customers to understand the best uses of blockchain, and we are excited about filing the first of many blockchain patents, with many more to come.

Epazz, Inc. (EPAZ), closed the day's trading session at $0.07, off by 2.78%, on 29,177 volume with 12 trades. The average volume for the last 60 days is 226,707 and the stock's 52-week low/high is $0.0045/$0.52.

Recent News

chart

Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF)

The QualityStocks Daily Newsletter would like to spotlight Choom Holdings Inc. (CHOOF).

NetworkNewsAudio announces the Audio Press Release (APR) titled "Early Regulations are Shaping the Future of Canadian Cannabis," featuring Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF). To hear the NetworkNewsAudio version, visit http://nnw.fm/7mjrC. To read the original editorial, visit http://nnw.fm/8KznA. Also today, NetworkNewsWire released a report on the company detailing how CHOOF stands to benefit as the unprecedented regulatory shift of forthcoming Canadian legalization is likely to unleash huge opportunities across multiple industry sectors, most notably cultivation and retail.

Choom Holdings Inc. (OTCQB: CHOOF) (CSE: CHOO) channels the laid-back spirit of Hawaii to the Okanagan region of British Columbia with a generous nod to the inspirational, yet unofficial, history of the 1970s “Choom Gang,” a group of buddies in Honolulu (including former President Barack Obama) who knew how to relax with “choom,” the local’s term for marijuana. Choom’s trademark slogans pivot off another unconventional phrase (“Say Hello to…”), bringing a heady dose of good times and good friends together as the company invites investors to “Say Hello to Choom™” as it lights up the adult recreational cannabis market in Canada.

Choom™ has been an ACMPR (Access to Cannabis for Medical Purposes Regulations) applicant since November 2013 in Vernon, B.C. The company’s first application has received security clearance and is now in the detailed review stage. They also recently announced their second late-stage ACMPR application, which is in its confirmation of readiness stage. Cannabis Compliance Inc. has been retained to help expedite Choom’s initial license applications to ensure the company’s readiness for legalization of recreational marijuana in Canada mid-summer 2018.

True to the company’s character, Choom™ is retrofitting two large facilities – No. 1 in Vernon, B.C., and No. 2 on Vancouver Island – to house its cannabis growing facilities. Phase 1 of the Vernon property will provide Choom™ with 6,800 square feet of growing space, capable of producing 660 kg/year of cannabis at an estimated revenue of $6.6 million, excluding oils. The company expects this facility to be completed by July 2018, the same month that Canada is expected to formally legalize recreational marijuana for adult use. A potential Phase 2, to be completed by the end of 2018, would add another 6,800 square feet for a total of 1,500 kg/year capacity, which would nearly double No. 1’s revenue. A Level 9 vault is also planned with a storage capacity of 15,000 kg. While the No. 2 facility on Vancouver Island is smaller – 4,500 square feet – its retrofit is also slated to be completed by July 2018. Plans include doubling this space as well, which would add about $9 million in annual revenue, excluding cannabis oils.

Choom™ announced its retail dispensary strategy with the intention of establishing market leadership in reaching the Canadian cannabis consumer. The partner program is already in the retail space design stage as the company seeks to build a chain of branded retail cannabis dispensaries in jurisdictions in Canada where recreational cannabis is legal. Choom™ Stores will have a cool, modern layout and design created to emit an authentic “Aloha” vibe. Choom™ is all about producing high-grade cultivars and curating them for a bigger audience.

A savvy, experienced management team includes Chris Bogart, president and CEO; John Oh, R.P.I.C., Operations Manager; Robert Bayrack, Master Grower, S.P.I.C.; and Adrian Robinson, Strategic Advisor. Bogart has over two decades of international experience in capital markets and was a co-founder of InMed Pharmaceuticals and Magnum Uranium. He has structured complex equity financing transactions in the U.S., Europe and Canada. Bogart is joined on the Board of Directors by Kevin Pull, Stephen Tong and John Oh.

While the medical marijuana industry is expected to double by 2021 to 500,000 registered users, the true highlight of the recreational cannabis represents the key cultural shift set to launch in Canada. With an estimated $4.9B to $8.7B retail market coming, now is the right time for a Recreation Brand like Choom™ to be involved in this growing industry. Establishing and maintaining Choom™ premium brand loyalty is a key factor in the company’s growth strategy. Get ready to “Say Hello” to opportunity, good times and good friends with Choom™.

Choom Holdings Inc. (CHOOF), closed the day's trading session at $0.6732, off by 4.63%, on 179,731 volume with 193 trades. The average volume for the last 60 days is 131,735 and the stock's 52-week low/high is $0.125/$0.8612.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

NetworkNewsAudio announces the Audio Press Release (APR) titled "Innovative Cannabis Delivery Technology Boosts Discovery, Momentum in Biotech Sectors," featuring Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP). To hear the NetworkNewsAudio version, visit: http://nnw.fm/7WYs1. To read the original editorial, visit: http://nnw.fm/av7QK.

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body’s gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria’s products and others on the market is the company’s disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the “unusual” taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria’s processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company’s patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria’s lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world’s most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $1.54, off by 3.75%, on 265,278 volume with 355 trades. The average volume for the last 60 days is 231,063 and the stock's 52-week low/high is $0.27/$2.54.

Recent News

Net Element (NASDAQ: NETE)

The QualityStocks Daily Newsletter would like to spotlight Net Element (NETE).

In a world with rapidly expanding opportunities for commerce at a truly worldwide scale, one of the greatest challenges businesses face is staying abreast of the technologies that keep people linked together across the globe. Net Element, Inc. (NASDAQ: NETE) is in the business of making business happen, ensuring that sales transactions can take place across a wide array of potential platforms, globally or in-person right at a merchant’s store. Also today, NETE was highlighted in an article on how markets may become more enthusiastic towards companies that are rushing to advance and improve blockchain technology to address the safety and security issues cryptocurrencies are now facing.

Net Element (NETE), is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce, and mobile devices. Net Element operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest growing companies in North America on Deloitte’s 2017 Technology Fast 500 ™ and South Florida Business Journal’s 2016 fastest growing technology companies.

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. Net Element’s all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

In a partnership with Bunker Capital, Net Element has also launched a new blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

“We believe that we’re at the dawn of a new evolution where additional digital payment methods are being introduced,” Net Element CEO Oleg Firer, says. “Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element’s growing network.”

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

  • Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012.
  • Digital Provider – A leading provider of SMS messaging and mobile billing solutions.
  • Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology.
  • Payonline – A fully integrated, processor agnostic electronic commerce platform.

Net Element is ranked No. 418 on Deloitte’s 2017 Technology Fast 500™ list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies. Net Element grew 190 percent. The company’s chief executive officer, Oleg Firer, credits the company’s progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

“The Deloitte 2017 North America Technology Fast 500 winners underscore the impact of technological innovation and world class customer service in driving growth, in a fiercely competitive environment,” said Sandra Shirai, vice chairman, Deloitte Consulting LLP and U.S. technology, media and telecommunications leader. “These companies are on the cutting edge, and are transforming the way we do business.”

Net Element’s suite of application performing interfaces (APIs) and connectors power commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

Net Element’s corporate team is led by director and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company’s mission of powering global commerce. He is joined by CFO Jonathan New, CPA, and Steven Wolberg, who is the company’s chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

From mobile payments and value-added transactional innovations such as Digital Provider and Aptito to e-commerce and retail payment transaction processing brands like Payonline and United Payments, Net Element is transforming the online and mobile experience.

Net Element (NETE), closed the day's trading session at $8.02, off by 9.28%, on 494,083 volume with 2,397 trades. The average volume for the last 60 days is 966,151 and the stock's 52-week low/high is $2.556/$33.51.

Recent News

chart

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE).

Global Payout Inc. (OTCPink:GOHE) (“Global”) is pleased to announce that, MoneyTrac Technology, Inc. (“MTRAC”, the “Company”), of which Global is a significant shareholder (currently 18% ownership), announced today that its PotSaver brand is expanding their sales and marketing efforts for MoneyTrac’s signature magazine publication by rolling-out a subscription-based model. Also today, CannabisNewsWire announced an Audio Press Release (APR) titled "Cannabis Industry Leads the Way in Payments Revolution," featuring Global Payout. To hear the NetworkNewsAudio version, visit http://nnw.fm/nJBk7. To read the original editorial, visit http://cnw.fm/9kfYD.

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout’s fully configurable “banking-in-a-box” web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today’s banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout’s management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and “high-risk” market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and “high-risk” enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions.

Global Payout, Inc. (GOHE), closed the day's trading session at $0.0209, off by 8.53%, on 18,496,580 volume with 430 trades. The average volume for the last 60 days is 12,095,490 and the stock's 52-week low/high is $0.0099/$0.16.

Recent News

chart

Virtual Crypto Technologies Inc. (OTCQB: VRCP)

The QualityStocks Daily Newsletter would like to spotlight Virtual Crypto Technologies Inc. (VRCP).

Virtual Crypto Technologies Inc. (OTCQB: VRCP), through wholly-owned Israeli subsidiary Virtual Crypto Technologies Ltd., has launched NetoBit Cash, a tablet device (http://nnw.fm/45Ywc) enabling video game suppliers and other businesses to securely buy, sell or convert bitcoin and other cryptocurrencies in real time.

Virtual Crypto Technologies Inc. (OTCQB: VRCP) is a developer of software and hardware for the purchase and sale of cryptocurrencies through ATMs, tablets, PCs and mobile devices. The company’s proprietary algorithmic technology trading platform, called NetoBit Trader, can instantaneously confirm the purchase or sale of Bitcoin, a process that typically can take between 10 minutes to 24 hours. All trades and exchanges are insured up to $3,000 per trade. The global cryptocurrency ATM market is predicted to surpass $285 million by 2025, yet, at present, only 30 percent of these machines allow two-way trades.

With NetoBit Trader, cryptocurrency holders enjoy immediate confirmation of Bitcoin and its crypto equivalents at the best crypto exchange rate at the point of transaction – providing a major breakthrough in the quest to bring cryptocurrencies to the mass market. Virtual Crypto’s cryptocurrency ATM, embedded with currency exchange transaction validation (CETV) in its hardware and software, accepts and dispenses cash and cryptocurrency in seconds.

Virtual Crypto’s NetoBit Trader and mobile retail point-of-sale platform incorporates advanced technologies tailored to the needs of primary market players, users, investors, and business owners. Virtual Crypto’s platform bridges the three main functions of the cryptocurrency sector – exchanges, wallets and payments – to the world of fiat exchanges, granting access to immediate cash exchanges between consumers and businesses worldwide.

NetoBit Trader’s over-the-counter, two-way transaction solution is available through one app, providing online cryptocurrency transactions at ecommerce and gaming portals. The app provides real-time cryptocurrency validation and exchange, easy buying and selling of Bitcoin with cash, enables traders to buy and trade crypto, and gamers to transfer cryptocurrency into cash after play. Crypto users can withdraw funds from their crypto accounts through a NetoBit cryptocurrency ATM or software-enabled tablet, and consumers can purchase retail with crypto from businesses that offer and use the NetoBit software.

The company’s newly redesigned corporate website, www.virtual-crypto.com, delivers a simple, clean design with enhanced functionality, features and navigation. Virtual Crypto’s new corporate website includes:

  • Downloadable NetoBit Trader app link and contact forms for more information
  • MarketWatch provides real-time tracking of the Bitcoin market, with other currencies to follow
  • Improved security utilizing https certificates to protect personal information and site integrity
  • Media room with downloadable product brochures, corporate presentations and other relevant content
  • Investor’s page provides transparency to investors with direct access to Virtual Crypto’s progress through press releases, SEC filings, senior management team bios, and stock performance charts
  • Social Media integration with buttons for LinkedIn, Twitter and Facebook jump to Virtual Crypto’s social media profiles, providing real-time updates from the online community

“Our primary objective is to make cryptocurrencies accessible to everyone, and that was the motivation for our redesign,” said Alon Dayan, Chief Executive Officer of Virtual Crypto. “The updated content provides real value for our customers, shareholders and employees, showcasing our products and services, in an intuitive, easy to navigate way.”

Virtual Crypto’s strategic vision of “Cryptocurrency Made Easy” allows crypto traders and users to overcome the complex hurdles currently hampering the cryptocurrency sphere.

Virtual Crypto Technologies Inc. (VRCP), closed the day's trading session at $0.20, off by 13.04%, on 25,404 volume with 12 trades. The average volume for the last 60 days is 26,646 and the stock's 52-week low/high is $0.0125/$0.38.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.